HIV/AIDS Research
HIV/AIDS research shows new drugs offer alternatives for individualized care
Published in AIDS Weekly, December 19th, 2005
Researchers presented data demonstrating that the newly approved anti-HIV drug Aptivus (tipranavir) provides a convincing and lasting benefit for patients whose virus has developed resistance to other anti-HIV medications. In addition, researchers presented new safety and efficacy analyses from a head-to-head study of Viramune (nevirapine) and efavirenz, for patients with less advanced HIV.
Combined findings from two studies, RESIST-1 and RESIST-2, demonstrate that...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-12-19)
More Articles from AIDS Weekly
- HIV/AIDS HAART
Initial therapy has diminished efficacy in patients with low CD4 counts and high viral loads - HIV/AIDS Neurotoxicity
Aciclovir protects against quinolinic acid-induced oxidative neurotoxicity - HIV/AIDS-Associated Pulmonary Hypertension
Secreted HIV gp120 proteins induce lung endothelial cell injury - Preventive Medicine
Safe male circumcision procedure offered in developing countries to decrease STD incidence - Bioethics
Controversies and interests drive 'Bioethics in action' - Cerebral Toxoplasmosis
PCR plus high titers of anti-Toxoplasma gondii IgG antibodies diagnose cerebral toxoplasmosis - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
